Parents' willingness to pay for coeliac disease screening of their child

Journal of Pediatric Gastroenterology and Nutrition

Volumn 52, Issue 4, 2011, Pages 452-459

  Norström, Fredrik ^a   Ivarsson, Anneli ^a   Lindholm, Lars ^a   Carlsson, Annelie ^b   Danielsson, Lars ^c   Högberg, Lotta ^d   Karlsson, Eva ^e   Löfgren, Curt ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c NORRTÄLJE HOSPITAL   (Sweden)

^d Norrköping University   (Sweden)

^e Vaxjo Hospital   (Sweden)

Author keywords

children; coeliac disease; cost benefit analysis; screening; willingness to pay

Indexed keywords

ARTICLE; CELIAC DISEASE; CHILD; COST BENEFIT ANALYSIS; EDUCATION; HUMAN; INCOME; MAJOR CLINICAL STUDY; PARENT; PARENTAL ATTITUDE; PRIORITY JOURNAL; QUESTIONNAIRE; SCREENING;

BIOLOGICAL MARKERS; CELIAC DISEASE; CHILD; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; EDUCATIONAL STATUS; FAMILY HEALTH; FEES AND CHARGES; FEMALE; HEALTH EXPENDITURES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH STATUS; HUMANS; INCOME; MALE; MASS SCREENING; PARENTS; QUESTIONNAIRES; SCHOOLS; SWEDEN;

EID: 79953835544     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182037efd     Document Type: Article

References (38)

1. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009;373:1480-93.
2. Kupper C. Dietary guidelines and implementation for celiac disease. Gastroenterology 2005;128:S121-7.
3. Fasano A, Catassi C. Coeliac disease in children. Best Pract Res Clin Gastroenterol 2005;19:467-78. (Pubitemid 40753766)
4. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001;120:636-51. (Pubitemid 32171637)
5. Ivarsson A, Persson LÅ, Juto P, et al. High prevalence of undiagnosed coeliac disease in adults: a Swedish population-based study. J Intern Med 1999;245:63-8. (Pubitemid 29049144)
6. Myleus A, Ivarsson A, Webb C, et al. Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J Pediatr Gastroenterol Nutr 2009;49:170-6.
7. Green PHR, Stavropoulos SN, Panagi SG, et al. Characteristics of adult celiac disease in the USA: results of a national survey. Am J Gastroenterol 2001;96:126-31. (Pubitemid 32104819)
8. Fasano A. Should we screen for coeliac disease? Yes. Br Med J 2009;339:b3592.
9. Mearin ML, Ivarsson A, Dickey W. Coeliac disease: is it time for mass screening? Best Pract Res Clin Gastroenterol 2005;19:441-52.
10. Wilson JMG, Jungner G. Principles and practice of screening for disease. WHO Chron 1968;22:473.
11. Evans KE, McAllister R, Sanders DS. Should we screen for coeliac disease? No. Br Med J 2009;339:b3674.
12. Kumar PJ. Antagonist - European and North American populations should be screened for coeliac disease. Gut 2003;52:170-1. (Pubitemid 36115053)
13. National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28-30, 2004. Gastroenterology 2005;128:S1-9.
14. Hershcovici T, Leshno M, Goldin E, et al. Cost effectiveness of mass screening for coeliac disease is determined by time-delay to diagnosis and quality of life on a gluten-free diet. Aliment Pharmacol Ther 2010;31:901-10.
15. Shamir R, Hernell O, Leshno M. Cost-effectiveness analysis of screening for celiac disease in the adult population. Med Decis Making 2006;26:282-93. (Pubitemid 43726014)
16. Harewood GC, Murray JA. Diagnostic approach to a patient with suspected celiac disease: a cost analysis. Dig Dis Sci 2001;46:2510-4. (Pubitemid 33042359)
17. Gomez JC, Selvaggio G, Pizarro B, et al. Value of a screening algorithm for celiac disease using tissue transglutaminase antibodies as first level in a population-based study. Am J Gastroenterol 2002;97:2785-90. (Pubitemid 35265430)
18. Dorn SD, Matchar DB. Cost-effectiveness analysis of strategies for diagnosing celiac disease. Dig Dis Sci 2008;53:680-8. (Pubitemid 351317092)
19. Spiegel BMR, DeRosa VP, Gralnek IM, et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004;126:1721-32. (Pubitemid 38736337)
20. Mein SM, Ladabaum U. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis. Aliment Pharmacol Ther 2004;19:1199-210. (Pubitemid 38746263)
21. Swigonski NL, Kuhlenschmidt HL, Bull MJ, et al. Screening for celiac disease in asymptomatic children with Down syndrome: cost-effectiveness of preventing lymphoma. Pediatrics 2006;118:594-602. (Pubitemid 46085415)
22. Hoffenberg EJ. Should all children be screened for celiac disease? Gastroenterology 2005;128:S98-103.
23. Collin P. Should adults be screened for celiac disease? What are the benefits and harms of screening? Gastroenterology 2005;128:S104-8.
24. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford University Press; 1997.
25. Carson RT, Flores NE, Meade NF. Contingent valuation: controversies and evidence. Environ Resource Econ 2001;19:173-210. (Pubitemid 32459257)
26. Champ PA, Boyle KJ, Brown TC. A Primer on Nonmarket Valuation. Dordrecht, The Netherlands: Kluwer Academic; 2003.
27. Murphy JJ, Allen PG, Stevens TH, et al. A meta-analysis of hypothetical bias in stated preference valuation. Environ Resource Econ 2005;30:313-25. (Pubitemid 40560742)
28. Frew EJ, Whynes DK, Wolstenholme JL. Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats. Med Decis Making 2003;23:150-9. (Pubitemid 36373397)
29. Stata Statistical Software: Release 10: College Station, TX: StataCorp; 2007.
30. Donaldson C. Valuing the benefits of publicly-provided health care: does 'ability to pay' preclude the use of 'willingness to pay'? Soc Sci Med 1999;49:551-63.
31. van Koppen EJ, Schweizer JJ, Csizmadia C, et al. Long-term health and quality-of-life consequences of mass screening for childhood celiac disease: a 10-year follow-up study. Pediatrics 2009;123:E582-8.
32. Philips Z, Whynes DK, Avis M. Testing the construct validity of willingness to pay valuations using objective information about risk and health benefit. Health Econ 2006;15:195-204. (Pubitemid 43193346)
33. Clarke PM. Testing the convergent validity of the contingent valuation and travel cost methods in valuing the benefits of health care. Health Econ 2002;11:117-27. (Pubitemid 34257014)
34. Cookson R. Willingness to pay methods in health care: a sceptical view. Health Econ 2003;12:891-4. (Pubitemid 37407334)
35. Ready RC, Buzby JC, Hu DY. Differences between continuous and discrete contingent value estimates. Land Econ 1996;72:397-411.
36. Hallert C, Grännö C, Hulten S, et al. Living with coeliac disease: controlled study of the burden of illness. Scand J Gastroenterol 2002;37:39-42. (Pubitemid 34074732)
37. Hallert C, Sandlund O, Broqvist M. Perceptions of health-related quality of life of men and women living with coeliac disease. Scand J Caring Sci 2003;17:301-7. (Pubitemid 41724465)
38. Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005;40:1-19. (Pubitemid 40180049)